Allworth Financial LP Has $2.04 Million Position in Becton, Dickinson and Company $BDX

Allworth Financial LP increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 17.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,840 shares of the medical instruments supplier’s stock after buying an additional 1,796 shares during the period. Allworth Financial LP’s holdings in Becton, Dickinson and Company were worth $2,039,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bill Few Associates Inc. raised its stake in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after acquiring an additional 55 shares during the last quarter. Gilbert & Cook Inc. raised its position in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after purchasing an additional 56 shares during the last quarter. Mendel Money Management lifted its holdings in Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 58 shares during the period. Plancorp LLC lifted its holdings in Becton, Dickinson and Company by 4.1% during the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock worth $343,000 after buying an additional 59 shares during the period. Finally, Moody National Bank Trust Division grew its position in shares of Becton, Dickinson and Company by 2.4% in the 2nd quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock valued at $445,000 after buying an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,249 shares of company stock valued at $231,358 over the last quarter. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.5%

BDX stock opened at $193.03 on Friday. The stock’s 50 day simple moving average is $186.65 and its 200 day simple moving average is $182.03. The company has a market cap of $55.33 billion, a P/E ratio of 34.72, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion during the quarter. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s payout ratio is 72.04%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BDX shares. Royal Bank Of Canada lowered their price objective on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research report on Friday, November 7th. Wells Fargo & Company raised their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group lowered their target price on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a research note on Friday, November 7th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus target price of $203.27.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.